Financial Performance - The company reported a basic earnings per share of -0.0500 yuan for Q1 2025, an improvement of 28.57% compared to -0.0700 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 10.7 billion yuan, representing a 12.28% increase from 9.53 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.54 billion yuan, showing a 23.94% improvement from -0.71 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.06%, an improvement from -1.28% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 57,163.5 million shares, accounting for 55.57% of the circulating shares, with an increase of 898.95 million shares compared to the previous period [1] - Shanghai Jiushi (Group) Co., Ltd. remains the largest shareholder with 37,376.75 million shares, representing 36.34% of the total share capital [2] - New entrants among the top shareholders include Wu Hongbin, Cheng Yiqing, Liu Zhiqiang, and Chen Weixing, while Qin Huiyu, Zhou Yue, Chen Yajing, and Zhu Yushu have exited the top ten shareholders [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

Core Viewpoint - The company, Northeast Pharmaceutical Group Co., Ltd., has disclosed its quarterly report, ensuring the accuracy and completeness of the financial information presented, and has not undergone an audit for this report [1][2][13]. Financial Data Summary - The company reported a significant increase in other current assets, with a year-end balance of 34.68 million yuan, reflecting a 31% growth compared to the beginning of the year, primarily due to changes in tax payments [4]. - The balance of notes payable decreased to 2.05 billion yuan, a reduction of 42% from the beginning of the year, attributed to a decrease in issued notes [5]. - The payable to employees dropped to 2.62 million yuan, down 94% from the beginning of the year, due to a reduction in employee compensation [5]. - The balance of taxes payable was 54.97 million yuan, a decrease of 31% from the beginning of the year, influenced by tax payments made during the period [5]. - Research and development expenses amounted to 32 million yuan, an increase of 88% year-on-year, indicating a higher investment in R&D [5]. - Financial expenses were reported at -7.68 million yuan, a decrease of 32% year-on-year, due to reduced interest expenses on bank loans [5]. - Investment income was 1.35 million yuan, down 41% year-on-year, primarily due to a decrease in debt restructuring amounts [5]. - The company reported a significant reduction in credit impairment losses, amounting to -5.87 million yuan, a decrease of 2380% year-on-year, due to an increase in accounts receivable [5]. - The asset impairment loss was -64.44 million yuan, a decrease of 71% year-on-year, attributed to an increase in inventory write-down provisions [5]. - The company recorded a net cash inflow from the disposal of fixed assets of 30,000 yuan, a decrease of 92% year-on-year, indicating reduced cash recovery from asset disposals [8]. - Cash received from bank borrowings was 14.4 billion yuan, an increase of 157% year-on-year, reflecting higher bank loan receipts [9]. - Cash paid for debt repayment was 9.92 billion yuan, an increase of 183% year-on-year, due to increased cash outflows for loan repayments [9]. Legal Matters - The company is involved in a legal dispute with a claim for economic damages of 32.7 million yuan and additional interest losses of approximately 25.15 million yuan, totaling 57.85 million yuan [15][16]. - The case has been accepted by the court and is scheduled for a hearing on May 12, 2025 [17]. - The company has stated that there are no other undisclosed significant litigation or arbitration matters as of the announcement date [18].

Core Viewpoint - The company has disclosed its first-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, with no significant omissions or misleading statements [2][10][20]. Financial Data Summary - The company reported a 36.66% decrease in cash and cash equivalents compared to the beginning of the period, primarily due to reduced sales collections and repayment of bank loans [4]. - Prepayments increased by 94.28%, attributed to higher advance payments for raw material purchases [4]. - Accounts payable decreased by 48.55%, mainly due to payments made for raw materials [4]. - Net cash flow from operating activities decreased by 105.36% year-on-year, resulting from a decline in revenue [5]. - Net cash flow from investing activities increased by 1.0988 million yuan year-on-year, due to the recovery of external investment funds [5]. - Net cash flow from financing activities increased by 62.43% year-on-year, primarily due to a reduction in bank loan repayments [5]. - Employee compensation payable decreased by 66.89% compared to the beginning of the period, due to the distribution of last year's performance bonuses [7]. - Tax payable decreased by 34.97%, mainly due to a reduction in value-added tax [7]. - Research and development expenses decreased by 38.34% year-on-year, attributed to reduced investment in R&D projects [7]. - Investment income decreased by 63.36% year-on-year, mainly due to a reduction in discount interest on notes [7]. Shareholder Information - The company has not reported any changes in the top ten shareholders or any significant shareholder lending activities [5]. Other Important Matters - The company is actively pursuing the recovery of external investment funds, with a total of 31.7482 million yuan owed by a partner, which has led to arbitration proceedings due to non-payment [6]. - A wholly-owned subsidiary has provided a guarantee for a financing loan of up to 5 million yuan from China Everbright Bank [7]. Board and Supervisory Meetings - The board of directors and the supervisory board have both approved the first-quarter report, confirming that the report complies with legal and regulatory requirements [12][20]. - The company has appointed a new securities affairs representative, Zhou Zexu, whose qualifications meet the necessary regulatory standards [24][26].

Financial Performance - The company reported a basic earnings per share of 0.0664 yuan for 2024, a significant increase of 290.59% compared to 0.0170 yuan in 2023 [1] - The net profit for 2024 reached 1.37 billion yuan, marking a substantial increase of 328.13% from 0.32 billion yuan in the previous year [1] - The operating revenue decreased to 7.57 billion yuan in 2024, down 23.77% from 9.93 billion yuan in 2023 [1] - The return on equity (ROE) fell to 10.59% in 2024, a decrease of 47.57% compared to 20.20% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 56,618.1 million shares, accounting for 34.05% of the circulating shares, with an increase of 27,882.76 million shares compared to the previous period [1] - New entrants among the top shareholders include Beijing Jingji Asset Private Equity Fund Management Co., Ltd. with 10,000 million shares (6.01%), and Shenzhen Shenyu Asset Management Co., Ltd. with 8,000 million shares (4.81%) [2] - Notable exits from the top shareholders include Shang Huazhong with 5,136.18 million shares and Dou Xin with 2,511.55 million shares [2][3] Dividend Policy - The company has announced no distribution or capital increase for the current period [4]

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.6849 | -0.8911 | 23.14 | -0.8576 | | 每股净资产（元） | 0.09 | 0.07 | 28.57 | 0.96 | | 每股公积金(元) | 5.69 | 5.08 | 12.01 | 5.09 | | 每股未分配利润(元) | -6.54 | -5.88 | -11.22 | -4.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 17.93 | 17.42 | 2.93 | 14.45 | | 净利润(亿元) | -2.53 | -3.32 | 23.8 | -3.21 | | 净资产收益率(%) | -237.81 | -173.39 | -37.15 | -55.31 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 10019.62万股 ...

Financial Performance - The company reported a basic earnings per share of -0.1314 yuan for 2024, an improvement of 83.45% compared to -0.7940 yuan in 2023 [1] - The total revenue decreased by 16.06% to 14.06 billion yuan in 2024 from 16.75 billion yuan in 2023 [1] - The net profit improved significantly to -0.79 billion yuan in 2024, a reduction of 83.33% from -4.74 billion yuan in 2023 [1] - The return on equity (ROE) increased to -4.36% in 2024 from -22.73% in 2023, marking an improvement of 80.82% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 93.923 million shares, accounting for 17.71% of the circulating shares, which is a decrease of 7.1722 million shares compared to the previous period [2] - The largest shareholder, Lu Wenbin, holds 24.409 million shares, representing 4.60% of the total share capital, with no change in holdings [3] - The second-largest shareholder, Wang Xiaoming, holds 17.368 million shares (3.27%), also unchanged [3] - Notable changes include a decrease of 1.43 million shares for Wang Xiaowei and a significant reduction of 44 million shares for Hong Kong Central Clearing Limited [3] Dividend Policy - The company has announced no distribution or capital increase for the current period [2]

一、主要会计数据和财务指标 前十大流通股东累计持有： 53484.26万股，累计占流通股比： 76.5%，较上期变化： 45310.08万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 湛江市对虾饲料有限公司 | 26461.20 | 37.85 | 新进 | | 香港煌达实业有限公司 | 16410.60 | 23.47 | 新进 | | 湛江承泽投资中心(有限合伙) | 5239.20 | 7.49 | 新进 | | 上海景商投资管理有限公司-景商鑫誉1号私募证券投 资基金 | 1291.57 | 1.85 | -1698.41 | | 广东粤海饲料（001313）集团股份有限公司回购专用 | | | | | 证券账户 | 1060.01 | 1.52 | 7.50 | | 东莞中科中广创业投资有限公司 | 808.50 | 1.16 | -106.00 | | 华夏行业景气混合 | 642.43 | 0.92 | 新进 | | 陈乐仪 | 532.56 | 0.76 | 185.24 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2000 | 0.1900 | 5.26 | 0.1700 | | 每股净资产（元） | 9.74 | 9.4 | 3.62 | 10.13 | | 每股公积金(元) | 5.74 | 5.68 | 1.06 | 6.27 | | 每股未分配利润(元) | 2.57 | 2.34 | 9.83 | 2.38 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 6.28 | 4.94 | 27.13 | 4.63 | | 净利润(亿元) | 0.54 | 0.5 | 8 | 0.41 | | 净资产收益率(%) | 2.11 | 2.04 | 3.43 | 2.57 | 数据四舍五入，查看更多财务数据>> | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0211 | -0.0419 | 49.64 | -0.0371 | | 每股净资产（元） | 3.4 | 3.44 | -1.16 | 3.48 | | 每股公积金(元) | 1.01 | 0.99 | 2.02 | 0.99 | | 每股未分配利润(元) | 1.22 | 1.29 | -5.43 | 1.33 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.9 | 1.59 | 19.5 | 1.3 | | 净利润(亿元) | -0.03 | -0.06 | 50 | -0.05 | | 净资产收益率(%) | -0.61 | -1.21 | 49.59 | -1.06 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5704.7万股，累计占流通股比： 39.62%，较上期变 ...

一、主要会计数据和财务指标 三、分红送配方案情况 本次公司不分配不转赠。 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0149 | -0.0384 | 138.8 | 0.0066 | | 每股净资产（元） | 3.39 | 3.49 | -2.87 | 3.96 | | 每股公积金(元) | 1.72 | 1.72 | 0 | 1.72 | | 每股未分配利润(元) | 0.40 | 0.51 | -21.57 | 0.98 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.15 | 1.16 | -0.86 | 1.1 | | 净利润(亿元) | 0.05 | -0.12 | 141.67 | 0.02 | | 净资产收益率(%) | 0.44 | -1.09 | 140.37 | 0.17 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 731 ...